DCP3 Series Acknowledgments

Disease Control Priorities, third edition *(DCP3)* compiles the global health knowledge of institutions and experts from around the world, a task that required the efforts of over 500 individuals, including volume editors, chapter authors, peer reviewers, advisory committee members, and research and staff assistants. For each of these contributions, we convey our acknowledgment and appreciation. First and foremost, we would like to thank our 33 volume editors who provided the intellectual vision for their volumes based on years of professional work in their respective fields, and then dedicated long hours to reviewing each chapter, providing leadership and guidance to authors, and framing and writing the summary chapters. We also thank our chapter authors who collectively volunteered their time and expertise to writing over 160 comprehensive, evidence-based chapters.

We owe immense gratitude to the institutional sponsor of this effort: The Bill & Melinda Gates Foundation. The Foundation provided sole financial support of the Disease Control Priorities Network. Many thanks to Program Officers Kathy Cahill, Philip Setel, Carol Medlin, and (currently) Damian Walker for their thoughtful interactions, guidance, and encouragement over the life of the project. We also wish to thank Jaime Sepúlveda for his longstanding support, including chairing the Advisory Committee for the second edition and, more recently, demonstrating his vision for *DCP3* while he was a special advisor to the Gates Foundation. We are also grateful to the University of Washington's Department of Global Health and successive chairs King Holmes and Judy Wasserheit for providing a home base for the *DCP3* Secretariat, which included intellectual collaboration, logistical coordination, and administrative support.

We thank the many contractors and consultants who provided support to specific volumes in the form of economic analytical work, volume coordination, chapter drafting, and meeting organization: the Center for Disease Dynamics, Economics & Policy; Centre for Chronic Disease Control; Centre for Global Health Research; Emory University; Evidence to Policy Initiative; Public Health Foundation of India; QURE Healthcare; University of California, San Francisco; University of Waterloo; University of Queensland; and the World Health Organization.

We are tremendously grateful for the wisdom and guidance provided by our advisory committee to the editors. Steered by Chair Anne Mills, the advisory committee assures quality and intellectual rigor of the highest order for *DCP3*.

The National Academy of Medicine, in collaboration with the InterAcademy Medical Panel, coordinated the peer-review process for all *DCP3* chapters. Patrick Kelley, Gillian Buckley, Megan Ginivan, and Rachel Pittluck managed this effort and provided critical and substantive input.

The World Bank External and Corporate Relations Publishing and Knowledge division provided exceptional guidance and support throughout the demanding production and design process. We would particularly like to thank Carlos Rossel, the publisher; Mary Fisk, Nancy Lammers, Rumit Pancholi, and Deborah Naylor for their diligence and expertise. Additionally, we thank Jose de Buerba, Mario Trubiano, Yulia Ivanova, and Chiamaka Osuagwu of the World Bank for providing professional counsel on communications and marketing strategies.

Several U.S. and international institutions contributed to the organization and execution of meetings that supported the preparation and dissemination of *DCP3*.

We would like to express our appreciation to the following institutions:

- University of Bergen, consultation on equity (June 2011)
- University of California, San Francisco, surgery volume consultations (April 2012, October 2013, February 2014)
- Institute of Medicine, first meeting of the Advisory Committee to the Editors (March 2013)
- Harvard Global Health Institute, consultation on policy measures to reduce incidence of noncommunicable diseases (July 2013)
- Institute of Medicine, systems strengthening meeting (September 2013)
- Center for Disease Dynamics, Economics & Policy (Quality and Uptake meeting, September 2013; reproductive and maternal health volume consultation, November 2013)
- National Cancer Institute, cancer consultation (November 2013)
- Union for International Cancer Control, cancer consultation (November 2013, December 2014)

Carol Levin provided outstanding governance for cost and cost-effectiveness analysis. Stéphane Verguet added invaluable guidance in applying and improving the extended cost-effectiveness analysis method. Shane Murphy, Zachary Olson, Elizabeth Brouwer, Kristen Danforth, and David Watkins provided exceptional research assistance and analytic assistance. Brianne Adderley ably managed the budget and project processes. The efforts of these individuals were absolutely critical to producing this series, and we are thankful for their commitment.

Series and Volume Editors

VOLUME EDITORS

Vikram Patel

Vikram Patel is Professor of International Mental Health and Wellcome Trust Principal Research Fellow at the London School of Hygiene & Tropical Medicine (LSHTM). He is a psychiatrist whose work focuses on the epidemiology and treatment of mental disorders in low-resource settings. He was the Founding Director of the Centre for Global Mental Health at the LSHTM and is the Co-Director of the Centre for Control of Chronic Conditions at the Public Health Foundation of India. In 2011, Dr. Patel served on the Government of India's Mental Health Policy group, which produced India's first national mental health policy in 2014.

Dan Chisholm

Dan Chisholm is a Health Systems Adviser in the Department of Mental Health and Substance Abuse at the World Health Organization. His main areas of work include development and monitoring of global mental health plans and activities, technical assistance to Member States on mental health system strengthening, and analysis of the costs and cost-effectiveness of strategies for reducing the global burden of mental disorders and other noncommunicable diseases.

Tarun Dua

Tarun Dua is a Medical Officer working in the Evidence, Research and Action on Mental and Brain Disorders unit in the Department of Mental Health and Substance Abuse at the World Health Organization. Dr. Dua serves as the focal point for neurological disorders in the organization.

Ramanan Laxminarayan

Ramanan Laxminarayan is Vice President for Research and Policy at the Public Health Foundation of India, and he directs the Center for Disease Dynamics, Economics & Policy in Washington, DC, and New Delhi. His research deals with the integration of epidemiological models of infectious diseases and drug resistance into the economic analysis of public health problems. He was one of the key architects of the Affordable Medicines Facility–malaria, a novel financing mechanism to improve access and delay resistance to antimalarial drugs. In 2012, he created the Immunization Technical Support Unit in India, which has been credited with improving immunization coverage in the country. He teaches at Princeton University.

María Elena Medina-Mora

María Elena Medina-Mora is the General Director for the National Institute of Psychiatry Ramón de la Fuente Muñiz in Mexico. She is a member of the National System of Researchers. Dr. Medina-Mora is a full researcher of the National Institutes of Health and has a teaching appointment in the National Autonomous University of Mexico and as Adjunct Professor in the Harvard T. H. Chan School of Public Health. She is also member of the World Health Organization's Expert Committee on Addictions.

SERIES EDITORS

Dean T. Jamison

Dean T. Jamison is a Senior Fellow in Global Health Sciences at the University of California, San Francisco, and an Emeritus Professor of Global Health at the University of Washington. He previously held academic

appointments at Harvard University and the University of California, Los Angeles; he was an economist on the staff of the World Bank, where he was lead author of the World Bank's *World Development Report 1993: Investing in Health*. He was lead editor of *DCP2*. He holds a PhD in economics from Harvard University and is an elected member of the Institute of Medicine of the National Academy of Sciences. He recently served as Co-Chair and Study Director of *The Lancet's* Commission on Investing in Health.

Rachel Nugent

Rachel Nugent is a Research Associate Professor in the Department of Global Health at the University of Washington. She was formerly Deputy Director of Global Health at the Center for Global Development, Director of Health and Economics at the Population Reference Bureau, Program Director of Health and Economics Programs at the Fogarty International Center of the National Institutes of Health, and senior economist at the Food and Agriculture Organization of the United Nations. From 1991–97, she was Associate Professor and Department Chair in Economics at Pacific Lutheran University. She has advised the World Health Organization, the U.S. government, and nonprofit organizations on the economics and policy environment of noncommunicable diseases.

Hellen Gelband

Hellen Gelband is Associate Director for Policy at the Center for Disease Dynamics, Economics & Policy (CDDEP). Her work spans infectious disease, particularly malaria and antibiotic resistance, and noncommunicable disease policy, mainly in low- and middle-income countries. Before joining CDDEP, then Resources for the Future, she conducted policy studies at the (former) Congressional Office of Technology Assessment, the Institute of Medicine of the National Academies, and a number of international organizations.

Susan Horton

Susan Horton is Professor at the University of Waterloo and holds the Centre for International Governance Innovation (CIGI) Chair in Global Health Economics in the Balsillie School of International Affairs there. She has consulted for the World Bank, the Asian Development Bank, several United Nations agencies, and the International Development Research Centre, among others, in work carried out in over 20 low- and middle-income countries. She led the work on nutrition for the Copenhagen Consensus in 2008, when micronutrients were ranked as the top development priority. She has served as Associate Provost of Graduate Studies at the University of Waterloo, Vice-President Academic at Wilfrid Laurier University in Waterloo, and interim dean at the University of Toronto Scarborough.

Prabhat Jha

Prabhat Jha is the Founding Director of the Centre for Global Health Research at St. Michael's Hospital and holds Endowed and Canada Research Chairs in Global Health in the Dalla Lana School of Public Health at the University of Toronto. He is Lead Investigator of the Million Death Study in India, which quantifies the causes of death and key risk factors in over two million homes over a 14-year period. He is also Scientific Director of the Statistical Alliance for Vital Events, which aims to expand reliable measurement of causes of death worldwide. His research includes the epidemiology and economics of tobacco control worldwide.

Ramanan Laxminarayan

See the list of Volume Editors.

Charles N. Mock

Charles N. Mock, MD, PhD, FACS, has training as both a trauma surgeon and an epidemiologist. He worked as a surgeon in Ghana for four years, including at a rural hospital (Berekum) and at the Kwame Nkrumah University of Science and Technology (Kumasi). In 2005–07, he served as Director of the University of Washington's Harborview Injury Prevention and Research Center. In 2007–10, he worked at the World Health Organization (WHO) headquarters in Geneva, where he was responsible for developing the WHO's trauma care activities. In 2010, he returned to his position as Professor of Surgery (with joint appointments as Professor of Epidemiology and Professor of Global Health) at the University of Washington. His main interests include the spectrum of injury control, especially as it pertains to low- and middle-income countries: surveillance, injury prevention, prehospital care, and hospital-based trauma care. He is President (2013–15) of the International Association for Trauma Surgery and Intensive Care.

Contributors

Emiliano Albanese
Department of Psychiatry, University of Geneva, Geneva, Switzerland

Margaret Barry
National University of Ireland Galway, Galway, Ireland

Amanda J. Baxter
School of Public Health, University of Queensland, Brisbane, Queensland, Australia; Queensland Centre for Mental Health Research, Wacol, Queensland, Australia

Vladimir Carli
Swedish National Center for Suicide Research and Prevention, Karolinska Institutet, Stockholm, Sweden

Fiona J. Charlson
School of Public Health, University of Queensland, Herston, Queensland, Australia; Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States

Pamela Y. Collins
U.S. National Institute of Mental Health, Bethesda, Maryland, United States

Abigail Colson
Center for Disease Dynamics, Economics & Policy, Washington, DC, United States; Department of Management Science, University of Strathclyde, Glasgow, Scotland

Louisa Degenhardt
National Drug and Alcohol Research Centre, University of New South Wales Australia, Sydney, New South Wales, Australia; Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia; Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States

Catherine O. Egbe
University of KwaZulu-Natal, Durban, South Africa; Center for Tobacco Control Research and Education, University of California San Francisco, San Francisco, California, United States

Holly E. Erskine
School of Public Health, University of Queensland, Herston, Queensland, Australia; Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States

Sara Evans-Lacko
Centre for Global Mental Health, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom

Valery Feigin
National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, Auckland, New Zealand

Abebaw Fekadu
Addis Ababa University, Addis Ababa, Ethiopia

Alize J. Ferrari
School of Public Health, University of Queensland, Herston, Queensland, Australia; Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States

Panteleimon Giannakopoulos
Department of Psychiatry, University of Geneva, Geneva, Switzerland

Petra Gronholm
Centre for Global Mental Health, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom

David Gunnell
University of Bristol, Bristol, United Kingdom

Wayne D. Hall
Centre for Youth Substance Abuse Research, University of Queensland, Brisbane, Queensland, Australia

Steven Hyman
Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, United States

David Jernigan
Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States

Nathalie Jette
University of Calgary, Calgary, Alberta, Canada

Kjell Arne Johansson
University of Bergen, Bergen, Norway

Carol Levin
Department of Global Health, University of Washington, Seattle, Washington, United States

Mattias Linde
Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway; Norwegian Advisory Unit on Headaches, St. Olavs Hospital, Trondheim, Norway

Crick Lund
Department of Psychiatry and Mental Health, Alan J. Flisher Centre for Public Mental Health, University of Cape Town, Cape Town, South Africa; Centre for Global Mental Health, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom

John Marsden
National Addiction Centre, King's College London, London, United Kingdom

Itamar Megiddo
Center for Disease Dynamics, Economics & Policy, Washington, DC, United States; Department of Management Science, University of Strathclyde, Glasgow, Scotland

Cathrine Mihalopoulos
Deakin University, Melbourne, Victoria, Australia

Maristela Monteiro
Pan American Health Organization, Washington DC, United States

Aditi Nigam
Center for Disease Dynamics, Economics & Policy, Washington, DC, United States

Rachana Parikh
Public Health Foundation of India, New Delhi, India

Inge Petersen
University of KwaZulu-Natal, Durban, South Africa

Michael R. Phillips
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Departments of Psychiatry and Global Health, Emory University, Atlanta, Georgia, United States

Martin J. Prince
Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom

Atif Rahman
University of Liverpool, Liverpool, United Kingdom

Neha Raykar
Public Health Foundation of India, New Delhi, India

Tania Real
National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico

Jürgen Rehm
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Jacqueline Roberts
Autism Centre of Excellence, Griffith University, Brisbane, Queensland, Australia

Robin Room
Centre for Alcohol Policy Research, La Trobe University, Melbourne, Victoria, Australia; Centre for Social Research on Alcohol and Drugs, Stockholm University, Stockholm, Sweden

Diego Sánchez-Moreno
Ministry of Health, Mexico City, Mexico

James G. Scott
University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia; Metro North Mental Health, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia

Maya Semrau
Centre for Global Mental Health, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom

Rahul Shidhaye
Public Health Foundation of India, New Delhi, India; CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, the Netherlands

Morton M. Silverman
Suicide Prevention Resource Center, Education Development Center, Waltham, Massachusetts, United States, The University of Colorado Denver School of Medicine, Aurora, Colorado, United States; The Jed Foundation, New York, New York, United States

Timothy J. Steiner
Norwegian University of Science and Technology, Trondheim, Norway; Imperial College London, London, United Kingdom

Emily Stockings
National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia

Kirsten Bjerkreim Strand
University of Bergen, Bergen, Norway

John Strang
National Addiction Centre, King's College London, London, United Kingdom

Kiran T. Thakur
Columbia University College of Physicians and Surgeons, New York, New York, United States

Graham Thornicroft
Centre for Global Mental Health, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, United Kingdom

Stéphane Verguet
Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States

Lakshmi Vijayakumar
SNEHA, Voluntary Health Services, Chennai, India; Centre for Youth Mental Health, University of Melbourne, Melbourne, Victoria, Australia

Theo Vos
Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States

Harvey A. Whiteford
School of Public Health, University of Queensland, Herston, Queensland, Australia; Queensland Centre for Mental Health Research, Wacol, Queensland, Australia; Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States

Advisory Committee to the Editors

Anne Mills, Chair
Professor, London School of Hygiene & Tropical Medicine, London, United Kingdom

Olusoji Adeyi
Director, Health, Nutrition, and Population Global Practice, World Bank, Washington, DC, United States

Kesetebirhan Admasu
Minister of Health, Addis Ababa, Ethiopia

George Alleyne
Director Emeritus, Pan American Health Organization, Washington, DC, United States

Ala Alwan
Director, World Health Organization, Regional Office for the Eastern Mediterranean, Cairo, Arab Republic of Egypt

Rifat Atun
Professor, Global Health Systems, Harvard University, Boston, Massachusetts, United States

Zulfiqar Bhutta
Chair, Division of Women and Child Health, Aga Khan University Hospital, Karachi, Pakistan

Agnes Binagwaho
Minister of Health, Kigali, Rwanda

Mark Blecher
Senior Health Advisor, South Africa Treasury Department, Cape Town, South Africa

Patricia Garcia
Dean, School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru

Roger Glass
Director, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States

Amanda Glassman
Director, Global Health Policy, Center for Global Development, Washington, DC, United States

Glenda Gray
Executive Director, Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Johannesburg, South Africa

Demissie Habte
Chair of Board of Trustees, International Clinical Epidemiological Network, Addis Ababa, Ethiopia

Richard Horton
Editor, *The Lancet*, London, United Kingdom

Edward Kirumira
Dean, Faculty of Social Sciences, Makerere University, Kampala, Uganda

Peter Lachmann
Professor, University of Cambridge, Cambridge, United Kingdom

Lai Meng Looi
Professor, University of Malaya, Kuala Lumpur, Malaysia

Adel Mahmoud
Senior Molecular Biologist, Princeton University, Princeton, New Jersey, United States

Anthony Measham
World Bank, Washington, DC, United States (retired)

Carol Medlin
Senior Health and Nutrition Specialist, Health, Nutrition, and Population Global Practice, World Bank, Washington, DC, United States

Alvaro Moncayo
Researcher, Universidad de los Andes, Bogotá, Colombia

Jaime Montoya
Executive Director, Philippine Council for Health Research and Development, Taguig City, the Philippines

Ole Norheim
Professor, University of Bergen, Bergen, Norway

Folashade Omokhodion
Professor, University College Hospital, Ibadan, Nigeria

Toby Ord
President, Giving What We Can, Oxford, United Kingdom

K. Srinath Reddy
President, Public Health Foundation of India, New Delhi, India

Sevkat Ruacan
Dean, Koç University School of Medicine, Istanbul, Turkey

Jaime Sepúlveda
Executive Director, Global Health Sciences, University of California, San Francisco, San Francisco, California, United States

Richard Skolnik
Lecturer, Health Policy Department, Yale School of Public Health, New Haven, Connecticut, United States

Stephen Tollman
Professor, University of the Witwatersrand, Johannesburg, South Africa

Jürgen Unutzer
Professor, Department of Psychiatry, University of Washington, Seattle, Washington, United States

Damian Walker
Senior Program Officer, Bill & Melinda Gates Foundation, Seattle, Washington, United States

Ngaire Woods
Director, Global Economic Governance Programme, Oxford University, Oxford, United Kingdom

Nopadol Wora-Urai
Professor, Department of Surgery, Phramongkutklao Hospital, Bangkok, Thailand

Kun Zhao
Researcher, China National Health Development Research Center, Beijing, China

Reviewers

Sergio Aguilar-Gaxiola
University of California, Davis, School of Medicine, Sacramento, California, United States

Pierre K. Alexandre
Management Department, College of Business, Florida Atlantic University, Boca Raton, Florida, United States

Peter Anderson
Newcastle University, Institute for Health and Society, Newcastle, United Kingdom

Margaret Barry
National University of Ireland Galway, School of Health Sciences, Galway, Ireland

Angelina Brotherhood
Centre for Public Health, Liverpool John Moores University, Liverpool, United Kingdom

Anja Busse
United Nations Office on Drugs and Crime, Vienna, Austria

Dixon Chibanda
Department of Community Medicine, University of Zimbabwe, Harare, Zimbabwe

Mary De Silva
Centre for Global Mental Health, London School of Hygiene & Tropical Medicine, London, United Kingdom

Tedla W. Giorgis
Office of the Minister, Ministry of Health, Addis Ababa, Ethiopia

Alexander Grinshpoon
Israel Institute of Technology, Haifa, Israel

Yasemin Gürsoy-Özdemir
Department of Neurology, Koç University School of Medicine, Istanbul, Turkey

Murad M. Khan
Aga Khan University, Karachi, Pakistan

Rena Kurs
Sha'ar Menashe Mental Health Center, Sha'ar Menashe, Israel

David Leon
London School of Hygiene & Tropical Medicine, London, United Kingdom

Ron Manderscheid
National Association of County Behavioral Health and Developmental Disability Directors, Washington, DC, United States

Pallab K. Maulik
George Institute for Global Health, India, New Delhi, India

David McDaid
London School of Economics and Political Science, London, United Kingdom

Nicole M. Monteiro
Center for Healing and Development, Washington, DC, United States

Chiadi U. Onyike
The Johns Hopkins Hospital, Baltimore, Maryland, United States

Gregory Simon
Group Health Research Institute, Seattle, Washington, United States

Jürgen Unützer
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, United States

Steven D. Vannoy
University of Massachusetts, Boston, Boston, Massachusetts, United States

Chiu-Wan Ng
Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia

Index

Boxes, figures, notes, and tables are indicated by b, f, n, and t respectively.

A

ACE (Assessing Cost-Effectiveness) prevention framework, 188
acupuncture, 91, 101
addiction. *See* illicit drug dependence
ADHD. *See* attention-deficit hyperactivity disorder
adolescents
  ADHD and, 146
  alcoholic consumption, heavy episodic drinking by, 128
  CBT for depression in, 222
  health loss in, 36
  interventions for
    drug use, early intervention for at-risk youth, 114
    mental health policies and plans, 148
  onset, 8, 194
  Resourceful Adolescent Programme-Adolescent version (RAP-A) program, 229–30, 230*t*
  suicides of, 171
adult mental disorders, 67–86
  burden of disease, 67–68
  extended-stay facilities to treat, 203
  interventions for, 73–78
    case detection and diagnosis, 77
    collaborative and stepped care, 77
    community outreach, 77–78, 79
    community platform interventions, 73–74
    cost-effectiveness of, 78
    early intervention services, 77
    family, 74, 79
    health care platform interventions, 74–78
    information and communication packages, 78
    mental health awareness campaigns, 73
    mental health legislation, 73
    occupational therapy, 76, 79
    packages of care, 76–77
    pharmacologic and psychological treatment, 74–76, 75–76*t*, 79
    population platform interventions, 73
    schools, 73–74
    workplace, 73
  mood and anxiety disorders, 68–72
    anxiety disorders, 70–71. *See also* anxiety disorders
    bipolar disorder, 71–72. *See also* bipolar disorder
    depressive disorder, 69–70. *See also* depression
  psychotic disorders, 72–73
  recommendations for, 78–79
  risk factors, 68
  schizophrenia, 72–73. *See also* schizophrenia
  suicide and, 169
  training gatekeepers to identify people with, 223
  YLDs and, 67–68, 68*f*
advertising bans on alcoholic beverages, 139
AEDs (anti-epileptic drugs), 88, 90, 91, 240
affordability. *See* cost-effectiveness and affordability of interventions
Africa. *See also specific countries and regions*
  alcohol consumption in, 129
  epilepsy in, 90
  illicit drug trade in, 111
  migraines in, 100
  suicide prevention organizations in, 176
  suicide rates in, 164, 169, 170
age as factor. *See also* adolescents; elderly persons
  for anxiety disorders, 70–71
  for cause-specific deaths from MNS disorders, 53, 54*t*

childhood disorders resulting in adult disorders, 146, 194
for dementia, 8
of suicide and self-harm, 164, 165*t,* 166–67*f,* 166*f*
Alcoholics Anonymous, 137
alcohol use disorders, 127–43
age of death attributable to, 53, 54*t*
binge drinking, 49, 128
burden of disease, 32–34*t,* 128–30
challenges for LMICs, 138–39
classification of beverages, 127
consequences, 129
co-occurring disorders and, 49–50
cost-effectiveness of interventions for, 19, 20*f,* 137–38, 139–40, 221–22, 226, 227*t*
DALYs and, 129
deaths associated with, 7*t,* 44, 129
fetal alcohol syndrome disorders (FASD), 128, 135, 139
GBD findings of excess mortality for
estimated number of cause-specific and excess deaths, 46*t,* 49
gender differences, 45, 46*f*
gender differences, 128–29
globalization of alcohol beverages industry, 128
indigenous communities and
community platform interventions, 135, 136*t*
prohibition, 131, 131*t*
industry role, 127–28
interventions for, 130–37
advertising bans, 139
availability control and licensing of sellers, 138
blood alcohol concentration (BAC) testing of drivers, 134
breath testing of drivers, 134
community platform interventions, 130–31, 135, 136*t*
control of unrecorded market, 133, 138–39
cross-border shopping, 133
delivery platforms, 14*t*
demand reduction strategies, 229, 229*f*
driving countermeasures, 134–35, 139
education campaigns, 139
family-based interventions, 135, 139
health care platform interventions, 135–37
individual-based, 130
law enforcement measures to reduce driving while impaired, 132*t*
mass media campaigns, 135
medical and social detoxification, follow-up, and referral, 136, 137*t,* 139
population platform interventions, 130, 131–35, 131*t*
pregnant women and, 135, 139
pricing and market regulation, 138
primary health care, 13–14*t,* 15
prohibition and partial bans, 131, 132*t*
quasi-experimental studies, 130
reducing availability of alcohol, 131
school-based, 19, 139
screening and brief interventions, 135–36, 136*t,* 139, 140
self-help and support groups, 136–37
sobriety checkpoints, 134
specialist health care delivery, 15
suspension of driver's license, 135
taxation, 131*t,* 132–33, 138, 221, 229
warning labels, 135, 139
liver cirrhosis and, 50
patterns of, 128
prohibition and partial bans, 131, 132*t*
public health considerations, 128
quasi-experimental studies, 130
recommendations for LMICs, 139
societal response, 130
suicide and, 50, 129, 169, 175
unintentional injuries and violence, 50, 129
YLLs and, 43–45, 45*f,* 53, 55, 55*t*
Alzheimer's disease. *See also* dementia
burden of disease, 32–34*t,* 94
DALYs and, 95
deaths associated with, 7*t,* 37, 53, 54*t*
goal to identify cure by 2025, 99
pharmacological interventions, 96, 98
amphetamine dependence. *See also* illicit drug dependence
amphetamine-type stimulants, 109
burden of disease, 32–34*t*
consumption trends, 111
deaths associated with, 7*t,* 110
age of death, 54*t*
estimated number of cause-specific and excess deaths for, 46*t,* 50*f*
prevalence in Southeast Asia and Australasia, 37
rates of dependence, 110
YLLs and, 43
Anderson, P., 19
anorexia nervosa, 3. *See also* eating disorders
antidepressants. *See* depression
anti-epileptic drugs (AEDs), 88, 90, 91, 240
antipsychotics
for dementia patients, 53, 96–97
for schizophrenia, 48
anxiety disorders, 70–71
age of onset, 70–71
burden of disease, 32–34*t,* 36, 70–71
childhood, 145
clinical features and course, 70

DALYs associated with, 36
deaths associated with, 7*t*
epidemiological surveys on, 38
epidemiology, 70–71
estimated number of cause-specific and excess deaths for, 46*t,* 49
gender differences, 68
generalized anxiety disorder, 70
interventions for, 9*t*. *See also* adult mental disorders
limited access to, 12
pharmacologic and psychological treatment, 74–76, 75*t*
primary health care, 13–14*t,* 15
self-care, 15
obsessive-compulsive disorder (OCD), 70
panic disorder, 70
simple phobias, 70
social anxiety disorder, 70
YLDs and, 68, 68*f*
Asia. *See also specific countries and regions*
amphetamine dependence in, 37
drug users, detention and treatment of, 58
illicit substance use in, 111
Asperger's syndrome, 36. *See also* autistic spectrum disorders
aspirin, 100–101
Assessing Cost-Effectiveness (ACE) prevention framework, 188
Atkins diet, 91
Atlas on Substance Use (WHO), 137
attention-deficit hyperactivity disorder (ADHD)
age of occurrence, 146
bipolar disorder and, 49
burden of disease, 32–34*t,* 36
cost-effectiveness of pharmacological interventions, 155
defined, 145
estimated number of cause-specific and excess deaths for, 46*t,* 49
interventions for, 9*t,* 12
medications, 154
school-based, 192
Australia
collaborative stepped care approach in, 210
drug dependence in
court-mandated treatment, 113
economic costs, 111
interventions, cost of, 118, 119
indigenous communities and alcohol consumption in, 131
mental health first aid course in, 188
methadone maintenance and buprenorphine maintenance in, 226
parenting interventions in, 155, 223
planning and consultation with primary health care staff in, 210
Positive Parenting Program (Triple P), 223
autistic spectrum disorders
age of cause-specific and excess deaths attributed to, 47*f*
burden of disease, 32–34*t,* 36
co-occurring disorders with, 48–49
deaths associated with, 7*t*
estimated number of cause-specific and excess deaths for, 46*t,* 47*f,* 48–49
interventions for, 9*t*

B

Babor, T. F., 135
Baker-Henningham, H., 150
Balanced Care Model, 207
Beijing Suicide Research and Prevention Center, 176
best practice interventions, 4*b,* 12, 15, 22, 56, 183, 184*t,* 188
binge drinking, 49, 128
bipolar disorder, 2
ADHD and, 49
adult bipolar disorder, 71–72
age of cause-specific and excess deaths attributed to, 47*f*
burden of disease, 32*t,* 34*t,* 71–72
clinical features and course, 71
cost-effectiveness of interventions for, 19, 227*t*
community-based vs. hospital-based services, 228
deaths associated with, 7*t*
epidemiology, 71–72
estimated number of cause-specific and excess deaths for, 46*t,* 47*f,* 48
gender differences, 68
interventions for. *See also* adult mental disorders
pharmacologic and psychological treatment, 74–76, 75*t*
specialist health care delivery, 15
YLDs and, 68, 68*f*
birth trauma, 185
blood alcohol concentration (BAC) testing of drivers, 134
Boussinesq, M., 52
Brazil
childhood mental and developmental disorders in
CBT for children with anxiety disorders, 154
community-based interventions, 149
collaborative stepped care approach in, 210
cost-effectiveness of drug therapy for schizophrenia and depression in, 225
primary care interventions in, 208
training of primary care workers, 210
specialists training primary health care staff in, 210

suicide in, 169, 170, 171, 172
Program for Promotion of Life and Suicide Prevention, 176
teacher training program to identify and assess mental health problems in, 191*b*
breath testing of drivers, 134
brief psychological intervention
for alcohol use disorders, 135–36, 136*t,* 139, 140
for drug dependence, 115, 116*t,* 117
for suicide, 177
Building Back Better (WHO), 204
bullying, 150, 156, 189
buprenorphine maintenance, 57, 117, 118, 119, 226
burden of MNS disorders, 4–5*b,* 5–8, 22, 29–40. *See also* mortality rates
adult mental disorders, 67–68
alcohol use disorders, 32–34*t,* 128–30
childhood mental and developmental disorders, 146
depression, 69–70
Global Burden of Disease Study 2010 (GBD 2010), 29–30. *See also* Global Burden of Disease Study 2010
illicit drug dependence, 32, 32–34*t,* 34, 111, 118
implications of study findings, 36–37
limitations of study and directions for future research, 37–38
methodology of study, 30–31
neurological disorders, 87
overview, 29–30
Burundi, integration of mental health care into primary care program, 17*b*

C

Canada
cost of Alzheimer's disease treatment in, 98
fetal alcohol syndrome (FAS) warning labels in, 135
TEAMcare Canada, 213
cancer, 41, 48, 49, 56
cannabis dependence. *See also* illicit drug dependence
burden of disease, 32–34*t*
cannabis products, 109
deaths associated with, 7*t,* 110
estimated number of cause-specific and excess deaths for, 46*t*
medications for, 118
rates of dependence, 110
schizophrenia and, 53, 55*t*
cardiovascular disease, 48, 51, 52, 56, 213
Carroll, A. E., 150
case studies. *See also* Ethiopia; India
scaling up interventions for MNS disorders, 16–17*b,* 24
catastrophic financial effects, 2*b*
Cause of Death Ensemble Modeling (CODEm), 42
CBT. *See* cognitive behavioral therapy
Central/Eastern Europe and Central Asia
alcohol-related deaths in, 44, 55
cost-effectiveness of interventions in, 221, 227*t*
suicide of women in, 171
YLL rates in, 44, 45–46*f,* 55
child abuse, 68, 146, 148, 152
Child and Adolescent Mental Health Policies and Plans (WHO), 148
childhood mental and developmental disorders, 145–61. *See also* attention-deficit hyperactivity disorder (ADHD); autistic spectrum disorders
anxiety disorders, 145, 146
bullying, 150, 156, 189
burden of disease, 146
consequences of, 146–47
cost-effectiveness of interventions, 155–56
epidemiology, 146
gender differences in, 5, 33, 146, 147*t*
interventions for, 9–10*t,* 12, 149–55, 149*b,* 156*t*
child and adolescent mental health policies and plans, 148
child protection legislation, 148–49
cognitive behavioral therapy (CBT), 153–55, 156
community platform interventions, 149–51
delivery platforms, 13*t*
early child development, 149–50
early intervention strategies, importance of, 36
health care platform interventions, 151–54
maternal mental health interventions, 152–53, 212
medications for ADHD, 154
medications for conduct disorder, 154
multisystem therapy, 155
parenting skills training, 152, 213–14
population platform interventions, 148–49
problem-solving skills therapy (PSST), 155
psychosocial treatments for conduct disorder, 154–55
school-based interventions, 150. *See also* education and schools
screening and community rehabilitation for developmental disorders, 151–52, 156
specialist health care, 154–55
Ten Questions screen, 151, 151*b*
voluntary sector programs, 150
nature of, 146
risk factors for, 146–48, 148*t*
trends, 148
types of, 145
Chile
CBT depression program in, 222

National Depression Detection and Treatment Program, 16–17*b,* 213
postpartum depression interventions in, 153, 207–8
school-based interventions in, 192
suicide rates in, 169
China
alcohol consumption in, 129
taxation, 133
violence associated with, 129
Central Government Support for the Local Management and Treatment of Severe Mental Illnesses Project, 16*b*
depression, treatment of, 70
drowning as premature cause of death in, 52
headache interventions in, 102, 208, 228*b*
suicide in, 164, 168, 170, 172, 175, 177
survey of mental disorders in, 38
Chisholm, D., 19, 232
CHOosing Interventions that are Cost-Effective (CHOICE) project (WHO), 220, 226, 228, 228*b,* 232
chronic or relapsing course, 1
cocaine dependence. *See also* illicit drug dependence
age of death attributable to, 54*t*
burden of disease, 32–34*t*
consumption trends, 111
deaths associated with, 7*t*
estimated number of cause-specific and excess deaths for, 46*t,* 50*f*
pharmacotherapies
effectiveness for, 58
for psychostimulant dependence, 118
prevalence in North American and Latin America, 37
rates of dependence, 110
YLLs and, 43
Cochrane Collaboration review, 207
CODEm (Cause of Death Ensemble Modeling), 42
cognitive behavioral therapy (CBT)
for adult mental disorders, 76
for childhood mental and developmental disorders, 153–55, 156
for depression, 225
in adolescents, 222
for illicit drug dependence, 117
maternal and child health programs, 212
school-based, 192
workplace, 188, 189
cognitive rehabilitation for dementia, 97, 213
collaborative care models, 56, 77, 79, 207
collaborative stepped care, 15, 77, 207–9, 213
Colombia, cost-effectiveness analysis of antidepressants in, 225
communicable compared to noncommunicable diseases in global burden of disease, 30, 36, 41
community-based care
for childhood mental and developmental disorders, 151–52, 156
compared to hospital level of care, 228
for illicit drug dependence, 114–15, 116*t*
residential facilities, 15–16, 203
community outreach teams, 16, 56, 77–78, 79
community platform interventions, 13–14*t,* 15, 187–92, 194
adult mental health, 73–74
alcohol use disorders, 130–31, 135, 136*t*
childhood mental and developmental disorders, 149–51
gender equity and economic empowerment interventions, 193
identification and case detection, 193
illicit drug dependence, 113–14, 115*t*
neighborhood groups, 192–93, 194
parenting. *See* parenting interventions
in schools. *See* education and schools
suicide and, 175–76
treatment, care, and rehabilitation, 193
workplace. *See* workplace
comparative risk assessments (CRAs), 6, 37, 42, 55*t,* 59
counterfactual burden and, 44, 53–56
competency-based education, 209–10, 209*t*
conduct disorders
burden of disease, 32–34*t,* 36
childhood, 145
deaths associated with, 7*t*
defined, 145
estimated number of cause-specific and excess deaths for, 46*t,* 49
interventions for, 9*t*
contingency management approach to drug dependence, 117
continuous quality improvement, 214
Convention on the Rights of Persons with Disabilities, 215
co-occurring disorders, 1, 8, 12, 47
alcohol use disorders and, 49
autistic spectrum disorders and, 48–49
bipolar disorders and, 48
dementia and, 52–53
epilepsy and, 52
integrating mental health into health programs for, 212–14
schizophrenia and, 48
coping strategies and well-being, 172
Corrigan, P. W., 187

cost-effectiveness and affordability of interventions, 12, 18–19, 20*f,* 219–36
for adult mental disorders, 78
affordability, 229–31
alcohol use, demand reduction strategies for, 229, 229*f*
costs of scaling up, 232*f*
school-based social and emotional learning interventions, 229–30
of alcohol-related legislation, 221–22
for alcohol use disorders, 19, 20*f,* 137–38, 139–40, 221–22
for childhood mental and developmental disorders, 155–56
CHOosing Interventions that are Cost-Effective (CHOICE) project (WHO), 220, 226, 228, 228*b,* 232
collaborative care models, 56
community-based parenting programs, 222–23
for dementia, 98–99
economic evaluation of treatment and prevention, 18*b*
for epilepsy, 19, 20*f,* 58, 90, 93
extended cost-effectiveness analysis (ECEA), 19, 21*f,* 238
financial risk protection, 19
for headache disorders, 102
for illicit drug dependence, 118, 120
lack of evidence, 12–15, 21
limitation of conventional cost-effectiveness analysis, 220
for MNS disorders, 223–29
by country, 224*f*
international studies, 226
national studies, 224–26
primary health care, 224–27
nonspecialized treatment settings, 230–31
overview, 219–20
paucity of trials, 219, 222, 230
population and community levels, 220–23
school-based social and emotional learning interventions, 222, 229–30
specialist health care delivery, 228–29
costs of mental health care, 237–38
counseling sessions, 76
court-mandated treatment for drug dependence, 112*t,* 113
criminal activity related to illicit drugs, 111, 119
criminal justice platforms, 112*t,* 113
cross-border shopping for alcohol, 133

D

DALYs. *See* disability-adjusted life years
DARE (Drug Abuse Resistance Education) program (US), 114
DART-AD (dementia antipsychotic withdrawal trial) trial, 53
decriminalization of suicide, 175
Degenhardt, L., 31
dementia, 93–99. *See also* Alzheimer's disease
age of death attributable to, 53, 54*t*
premature death, 41
age of onset, 8
burden of disease, 30, 32–34*t,* 87, 94–95, 94*f,* 95
caregiver stress, 95, 97
coping strategy program, cost-effectiveness of, 225
community health workers' detection abilities, 193
co-occurring disorders and, 52–53
cost-effectiveness of interventions for, 98–99
cost of, 8
definitions of, 31, 93–94
detection and diagnosis, 96
early-onset dementia, 94
epidemiology, 94–95
GBD findings of excess mortality for
estimated number of cause-specific and excess deaths, 46*t,* 51*f,* 52–53
implications, 58
interventions for, 10*t,* 96–98, 186
capacity of health care teams, 97–98
caregivers, 97
community-based programs, 98
health care delivery interventions, 97
integration into health care, 213
nonpharmacological interventions, 97
other interventions, 98–99
pharmacological interventions, 96–97, 98
specialist health care delivery, 15
recommendations for, 103
YLLs and, 43, 45*f*
dementia antipsychotic withdrawal trial (DART-AD) trial, 53
Dementia Society of Goa, 207
demographic factors, 3*b*
depression, 69–70. *See also* bipolar disorder; postpartum depression
age of cause-specific and excess deaths attributed to, 47*f*
alcohol use disorders and, 49–50
antidepressants, 56, 75*t,* 225, 226
burden of disease, 32, 32–34*t,* 34, 36
chronic illnesses associated with, 68
clinical features and course, 69
co-occurring disorders with, 47, 56, 69
cost-effectiveness of interventions for, 19, 20*f,* 227*t,* 230
antidepressants and CBT, 225, 226
enhanced financial and service coverage, 243–44

DALYs associated with, 36
deaths associated with, 6, 7*t*
epidemiological surveys on, 38
epidemiology and burden of disease, 69–70
estimated number of cause-specific and excess deaths for, 46*t,* 47*f,* 49
gender differences, 68
interventions for, 8, 9*t,* 12, 75*t*
collaborative care, 207
electroconvulsive therapy (ECT), 74
European Alliance against Depression Programme, 176
limited access to, 12
primary health care, 13–14*t,* 15, 207–8
psychosocial interventions for adolescents, 190
self-care, 15
specialist health care delivery, 15
transcranial magnetic stimulation as treatment for, 74
serotonin-norepinephrine reuptake inhibitors (SNRIs) and, 225
suicide and, 69, 176
YLDs and, 68, 68*f*
YLLs and, 49
detoxification
alcohol use disorders, 136, 137*t,* 139
substance abuse, 116, 120
developed countries. *See* high-income countries (HICs)
developing countries. *See* low- and middle-income countries (LMICs)
developmental disorders, children with. *See* childhood mental and developmental disorders
developmental disorders, people with, 48. *See also* childhood mental and developmental disorders
diabetes, 41, 56, 128, 129, 184, 213
3 Dimensions of Care for Diabetes (UK), 213
Diagnostic and Statistical Manual of Mental Disorders (DSM), 31
DSM-4, 110, 208
DSM-5, 71–72, 110
disability-adjusted life years (DALYs)
alcohol use disorders and, 129
caused by MNS disorders, 5, 30–35, 31*f,* 32*t,* 34*t*
cost per DALY averted, 18, 19, 20*f*
gender differences, 32–33, 32*t,* 34–33, 34*f,* 34*t*
illicit drug dependence and, 36, 111
disasters and refugees, 177
Disease Control Priorities in Developing Countries, 2*b*
DisMod-MR, 43, 47, 49, 59
disruptive behavioral disorders. *See* attention-deficit hyperactivity disorder (ADHD); conduct disorders
domestic violence legislation, 186
Dretzke, J., 155
driving impaired and traffic accidents, 49, 129, 137
cost-effectiveness of countermeasures, 221
countermeasures for, 134–35, 139
helmet laws, 186
Drug Abuse Resistance Education (DARE) program (US), 114
drug dependence. *See* illicit drug dependence
drug education, 114, 115*t*
drug testing
of offenders, 112*t,* 113
in workplace, 113–14, 115*t*
Drummond, M. F., 220

E

early child development, 149–50, 192–93
early intervention
drug dependence of at-risk youth, 114
for psychosis treatment, 77
East Asia and Pacific
alcohol consumption in
cost-effectiveness of interventions, 137, 221
driver testing and arrest, 135
taxation, 133, 137
cost-effectiveness of interventions in, 227*t,* 239
suicide prevention organizations in, 176
suicide rates in, 164
traditional medicine in, 202
YLLs in, 44, 45–46*f*
Eastern Europe. *See* Central/Eastern Europe and Central Asia
Eastern Mediterranean Region
suicide in, 170
WHO proposed regional framework in, 23–24*b*
eating disorders, 3, 32–34*t*
ECEA. *See* extended cost-effectiveness analysis
economic effects
of illicit drug dependence, 111
of mental, neurological, and substance use (MNS) disorders, 8
economic evaluation of treatment and prevention, 18*b*. *See also* cost-effectiveness and affordability of interventions
ECT (electroconvulsive therapy), 74
education and schools
alcohol education campaigns, 139
early childhood enrichment programs, 192–93
epilepsy education, 58
illicit drug dependence
drug education, 114, 115*t*
skills training, 114, 115*t*
mental health awareness, 73–74
overdose prevention education, 114–15
peer-led education, 202
preschool educational programs, 192–93

school-based interventions, 189–92, 194
alcohol use, 19, 139
childhood mental and developmental disorders, 150
emergency response, 190, 191*b*
HealthWise program (South Africa), 190, 190*b*
identification and case detection, 190–91
illicit drug dependence, 114, 115*t*
information and awareness, 189
Mental Health First Aid for High School Teachers, 191
social and emotional learning interventions, 189–90, 222, 229–30
suicide and self-harm, 176
teacher training program, 191*b*
treatment, care, and rehabilitation, 192
for vulnerable children, 190
whole-of-school approaches, 150
Egypt
childhood mental and developmental disorders, community-based interventions in, 149
suicide in, 170
Eickmann, S. H., 149
elderly persons. *See also* Alzheimer's disease
Home Care Program for (Goa), 207
neurological disorders in, 36
suicide rates of, 164
electroconvulsive therapy (ECT), 74
emergency response
drug-related interventions, 115
humanitarian aid, 16
mental health care, 204
school-based interventions, 190, 191*b*
environmental events, 3*b*
epilepsy, 88–93
alcohol use disorders and, 49
anti-epileptic drugs (AEDs), 88, 90, 91, 240
autistic spectrum disorders and, 48
birth trauma and, 185
burden of disease, 30, 32–34*t,* 87, 88–89
co-occurring disorders and, 52
cost-effectiveness of interventions for, 19, 20*f,* 58, 90, 93, 227*t*
extended cost-effectiveness analysis, 241*t*
DALY ranking of, 90
deaths associated with, 7*t,* 41
age of death, 53, 54*t*
definition of, 31, 88
epidemiology, 88–89
GBD findings of excess mortality for
estimated number of cause-specific and excess deaths, 46*t,* 51–52, 51*f*
implications, 58
gender differences in, 5, 33
interventions for, 8, 10*t,* 89–93
alternative therapies, 91
anti-stigma interventions, 89–90
helmet laws, 186
legislation, 90
management of infectious etiologies, 91
optimizing health care delivery, 91–92
pharmacological interventions, 58, 90–91
population platform interventions, 89
primary health care, 13–14*t,* 15
self-management, 90, 203
surgical management, 91, 93
treatment gap, 58, 92*f,* 93*b*
mental illness and, 52
recommendations for, 103
status epilepticus, 88
suicide and, 52
YLDs and, 90
YLLs and, 43–45, 45*f*
Ethiopia
alcohol use, demand reduction strategies for, 229
cost-effectiveness of interventions in, 18*b*
depression interventions in, 248*t*
productivity impact of scaled-up treatment, 246–47
extended cost-effectiveness analysis of publicly financed mental and neurological health care package in, 245–46, 247*t*
comparison with India, 249*t*
parenting skills training in, 152
school-based social and emotional learning intervention in, 230
European Alliance against Depression Programme, 176
European Headache Federation, 208
evidence-based interventions for health care delivery, 204, 205*t*
extended cost-effectiveness analysis (ECEA), 19, 21*f,* 238
application to MNS disorders, 238, 239
comparison of India and Ethiopia, 249*t*
Ethiopia analyses, 245–48
Indian analyses, 240–45
principles and practice, 238

F

faith-based organizations, 202
family impacts and involvement, 1
alcoholics, family-based interventions for, 135, 139
family history of suicide, 170
illicit drug dependence, 110
in treatment, 74, 79
farmers, suicides of, 171

Farrington, D. P., 150
fetal alcohol syndrome disorders (FASD), 128, 135, 139
financial risk protection (FRP), 19, 203, 238, 239*b*
Finland
  Alzheimer's disease, pharmacological interventions for, 98
  epilepsy-related deaths in, 52
  illicit drug use in, 111
  workplace treatment, care, and rehabilitation in, 189
fluoxetine, 226
folic acid
  deficiency, 94
  food fortification, 185
forensic psychiatry, 203
fragile X syndrome, 48–49
France
  APPRAND program, 188
  fetal alcohol syndrome (FAS) warning labels in, 135
FRP (financial risk protection), 19, 203, 238, 239*b*
Fuhr, D., 19

G

gatekeeper training, 176, 223
GBD. *See* Global Burden of Disease Study 2010 (GBD 2010)
gender differences in burden of MNS disorders, 5, 32–34, 32*t,* 34*f,* 34*t,* 68
  alcoholic consumption, 128–29
  childhood mental and developmental disorders, 5, 33, 146, 147*t*
  illicit drug dependence, 5, 45, 46*f*
  suicide and, 164, 165*t,* 166–67*f*
  YLLs and, 45, 46*f*
generic drugs. *See* medications
genotyping, 68
Global Burden of Disease Study 2010 (GBD 2010), 3, 29–30. *See also* burden of MNS disorders
  comparative risk assessments. *See* comparative risk assessments (CRAs)
  excess mortality from MNS disorders, 41–65
    assessment as risk factors for other health outcomes, 44. *See also* co-occurring disorders
    cause-specific death estimates, 42, 44–53. *See also specific MNS disorders*
    implications, 56–58
    methodology of study, 42–44. *See also* years of life lost (YLLs)
  transition from communicable to noncommunicable diseases, 30, 36, 41
Global Burden of Disease Study 2013 (GBD 2013), 38
Global Campaign against Headache, 101
Global Campaign against Headache for Europe, 102, 208
Global Health Estimates of disease burden, 5
globalization of alcohol beverages industry, 128
Gmel, G., 133
Good Behavior Game (US), 114
good practice interventions, 12, 15, 183, 184*t,* 188, 193, 214
Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines, 8, 130–31
Gunnell, D., 17*b*

H

Handwerk, M., 155
Happell, B., 56
HCV (hepatitis C), 51, 57, 111, 119
headache disorders, 99–102. *See also* migraine
  burden of disease, 100
  cost-effectiveness of interventions for, 102
  epidemiology, 100
  interventions for, 100–101, 188
    alternative therapies, 101
    optimizing health care delivery, 102, 208
    pharmacological interventions, 100–101
    public education programs, 101–2
    self-management, 100
    training health care providers, 102
  medication-overuse headache, 99–100
  recommendations for, 103
  tension-type headache, 99
Headache Management Trial, 208
health care platform interventions, 4*b,* 13–14*t,* 15–16, 201–18
  for alcohol use disorders, 135–37. *See also* alcohol use disorders
  for childhood mental and developmental disorders, 151–54. *See also* childhood mental and developmental disorders
  collaborative stepped care. *See* collaborative stepped care
  for depression, 70
  elements of, 201–4
  emergency mental health care, 204. *See also* emergency response
  evidence-based, 204
  hospital level of care, 13–14*t,* 15, 203
  for illicit drug dependence, 114–18, 116*t*. *See also* illicit drug dependence
  integrating mental health into existing health programs, 212–14
  for mood and psychotic disorders, 74–78
  primary level. *See* primary health care level
  PRogramme for Improving Mental health carE (PRIME), 209, 231

for psychiatric services, 203
quality of care, 15, 214–15
relationships among difference delivery channels, 204
self-care and informal health care, 202–3. *See also* self-care
specialists. *See also* specialist health care delivery
training primary health care staff by, 210
for suicide, 177–78
system-strengthening strategies for, 204–9
task-sharing approach, 209–12, 210*b*
Healthnet Transcultural Psychosocial Organization (TPO), 17*b*
HealthWise program (South Africa), 190, 190*b*
hepatitis B, 51, 111
hepatitis C (HCV), 51, 57, 111, 119
heroin. *See* illicit drug dependence; opioid dependence
high-income countries (HICs). *See also specific countries*
alcoholic consumption in, 128, 138
burden of MNS disorders in, 5, 29
cost-effectiveness of interventions in, 19
drug dependence treatments and interventions, 118
dementia care costs in, 95*f*
epilepsy-related deaths in, 51
intervention delivery platforms in, 12
screening children for developmental disorders, 151–52
specialist services, 2
Hip Hop Stroke (awareness program for children), 189
HIV/AIDS
alcohol use and, 184
anti-epileptic drugs for people with, 91
burden of disease, 57
cost-effective prevention strategy, 226
dementia and, 94
illicit drug use and, 51, 58, 110–11, 115, 119
integrating mental health into existing programs for, 212
mental health needs of persons with, 213–14
methadone maintenance and, 117, 118
suicide and, 169
HIV antiretroviral therapy, 57
home care programs, 207
Honduras, epilepsy treatment in, 89, 186
hospital level of care, 13–14*t,* 15, 203
cost-effectiveness of, 228–29
humanitarian aid and emergency response, 16, 204
human rights violations, 58, 67, 214, 215

I

ibuprofen, 100
ICD-10. *See* International Classification of Diseases
illicit drug dependence, 109–25. *See also* amphetamine dependence; cannabis dependence; cocaine dependence; opioid dependence
age of death attributable to, 54*t*
burden of disease, 32, 32–34*t,* 34, 111, 118
consequences, 110–11
consumption trends, 111
cost-effectiveness of interventions, 118, 120
criminal activity, 111, 119
DALYs associated with, 36, 111
definition of, 31, 109–10, 120*n*1
delivery platforms for, 14*t*
economic costs of, 111
externalizing disorders, 114, 120*n*4
family factors, 110
GBD findings of excess mortality for
estimated number of cause-specific and excess deaths, 49, 50*f,* 51
implications of, 57–58
gender differences in, 5, 45, 46*f*
global trends, 111
implications for low- and middle-income countries, 118–19
individual factors, 110
injecting drug risks, 51, 53, 55*t,* 57, 226
internalizing disorders, 114, 120*n*4
interventions and policies, 11*t,* 111–18
access to treatment, 114
brief psychological intervention, 115, 116*t,* 117
cognitive behavioral therapy (CBT), 117
community-based care, 114–15, 116*t*
community platform interventions, 113–14, 115*t*
contingency management approach, 117
control of supply, 112
court-mandated treatment, 112*t,* 113
criminal justice platforms, 113
delivery platforms for, 14*t*
detoxification and withdrawal, 116, 120
drug education, 114, 115*t*
drug testing of offenders, 112*t,* 113
early intervention with at-risk youth, 114
health care platform interventions, 114–18, 116*t*
imprisonment, 112*t,* 113, 120
law enforcement, 112, 112*t,* 119–20
legislation, 186
medication for cannabis dependence, 118
medication for heroin and opioid dependence, 116*t,* 117
naloxone and other emergency responses, 115
overdose prevention education, 114–15
population platform interventions, 112–13, 112*t*
prescription monitoring programs, 112–13, 112*t*
primary health care, 13–14*t,* 15, 115, 116*t*

psychosocial interventions, 117
public awareness campaigns, 112*t,* 113
residential rehabilitation, 117
school-based prevention programs, 114, 115*t*
self-help and mutual aid groups, 114, 115*t*
skills training in schools, 114, 115*t*
specialist health care delivery, 15, 116–17, 116*t*
supervised injecting facilities, 57, 115
therapeutic community (TC) model, 117
workplace drug testing, 113–14, 115*t*
medical vs. moral models of addiction, 12, 119
mortality rates, 110–11
narcotic antagonists, 119, 120, 120*n*6. *See also* buprenorphine maintenance; naltrexone maintenance
natural history of dependence, 110
novel psychoactive substances, 109, 120*n*2
peer group factors, 110
pharmacotherapies, effectiveness of, 57–58
polydrug use, 114, 120*n*5
precursor chemicals, 112, 112*t,* 120*n*3
recommendations, 119–20
research needs, 119, 120
risk factors, 110
social and contextual factors, 110
suicide and, 51, 55*t,* 110, 175
YLLs and, 45*f,* 53, 110
gender differences and, 45, 46*f*
imprisonment for drug offenses, 112*t,* 113, 120
India
alcohol consumption in, 129
demand reduction strategies for, 229
taxation on, 133
unrecorded production and consumption, 221
collaborative care for mental illnesses in, 77
community-based rehabilitation in, 78
cost-effectiveness of interventions in, 18*b*
depression, 230, 243–44, 244*t*
extended analysis for schizophrenia, 19, 21*f*
Dementia Society of Goa, 207
District Mental Health Programme, 208
education and schools in
examination stress, 175
teacher training for youth health promotion program, 222
teacher training to improve epilepsy knowledge, 191
epilepsy interventions in, 240, 241*t*
extended cost-effectiveness analysis (ECEA), 240–45
comparison with Ethiopia, 249*t*
headache interventions in, 228*b*
MANAS (MANashanti Sudhar Shodh, or project to promote mental health), 78, 207, 224–25
maternal and infant health programs in, 153
National Sample Survey Organization, 238
pesticide ban in, 185
school-based social and emotional learning intervention in, 230
suicide in, 168, 170, 178
religious and spiritual beliefs, 172
safe storage of pesticides, 176
universal health coverage, 240, 245*f*
indigenous communities and alcohol consumption
community platform interventions, 135, 136*t*
prohibition, 131, 131*t*
individual factors
alcohol use disorders, 130
illicit drug dependence, 110
infants
immunization programs for, 185
maternal and infant health programs, 153
psychosocial interventions for, 149, 150
salt iodization programs for, 185
informal health care. *See* self-care
information and communication packages, 78
injecting drug risks, 51, 53, 55*t,* 57, 226
Institute for Health Metrics and Evaluation at University of Washington, 38
Institute of Medicine's Forum on Neuroscience and Nervous System Disorders, 209
intellectual disability
burden of disease, 32–34*t*
childhood, 145
defined, 145
effective interventions for, 10*t*
Inter-Agency Standing Committee's *Guidelines on Mental Health and Psychosocial Support in Emergency Settings,* 204
International Classification of Diseases (ICD-10), 5, 31, 35, 37, 42, 46, 49, 72, 109, 168
International Convention on the Rights of Persons with Disabilities, 186
International Labour Organization, 188
International League against Epilepsy, 88
interventions for MNS disorders, 8–12
for adult mental disorders, 73–78. *See also* adult mental disorders
for alcohol use disorders, 130–37. *See also* alcohol use disorders
case studies, 16–17*b*
for childhood mental and developmental disorders, 149–55. *See also* childhood mental and developmental disorders
collaborative care models, 56
community-based. *See* community platform interventions

costs. *See* cost-effectiveness and affordability of interventions
delivery platforms of, 12–17, 13–14*t*
for dementia, 96–98
effective essential interventions, 8–12, 9–11*t*
health care. *See* health care platform interventions
for illicit drug dependence, 11*t,* 111–18. *See also* illicit drug dependence
limited access to, 12
population-based. *See* population platform interventions
quality of care, 15, 214–15
iodine deficiency, 185
Iran, suicide in, 176, 177
Israel
community-based interventions for childhood mental and developmental disorders, 149
Heart Disease study, 52

J

Jamaica
childhood emotional and behavioral problems in, 150
psychosocial interventions for malnourished infants in, 149, 150

K

Kamgno, J., 52
Kenya
epilepsy-related deaths in, 52, 88
epilepsy treatment in, 89
training of primary care workers in, 210
ketogenic diet, 91
key messages, 4*b*
Kilian, R., 155
knowledge gaps, effect on scaling up, 21–22
Korea, Republic of
dementia detection program in, 98
suicide in, 175

L

Lachenmeier, D., 133–34
Latin America and the Caribbean
alcohol consumption in, 129
cost-effectiveness of interventions, 137, 221
partial bans on, 132
self-help and support groups, 136, 137
taxation on, 132–33
cost-effectiveness of interventions in, 221, 226, 227*t*
substance use disorders in, 44
suicide in
religious and spiritual beliefs, 172
risk factors, 169
survivors of suicide loss, 172
traditional medicine in, 202
YLLs in, 44, 45–46*f*
law enforcement
alcohol use disorders and, 132*t*
illicit drug dependence and, 112, 112*t,* 119–20
legislation
on alcoholic beverages, 221–22
child protection legislation, 148–49
on epilepsy, 90
illicit drugs legislation, 186
mental health legislation, 73
restricting access to lethal means of suicide, 17*b,* 176, 185, 194, 222
licensing of alcoholic beverages sellers, 138
life expectancy gap in people with mental disorders, 41, 42, 57. *See also* years of life lost (YLLs)
lifestyle risk factors, 47, 56–57, 58, 101
Lim, S. S., 44, 129
List of Essential Medicines (WHO), 57
liver cirrhosis, 50, 184
low- and middle-income countries (LMICs). *See also specific countries*
alcohol consumption in, 128
challenges for, 138–39
cost-effective interventions, 221
mortality rates associated with, 130
recommendations for, 139
burden of MNS disorders in, 29
cause-of-death data from, 58
childhood mental and developmental disorders, community-based interventions in, 149
dementia care costs in, 95*f*
epilepsy-related deaths in, 51
epilepsy treatment gap in, 58, 92*f*
illegal substance dependence in
assessment issues, 118
burden of disease, 118
cost-effectiveness of interventions, 118
health care infrastructure and capacity, 119
implications, 118–19
medical vs. moral models of addiction, 119
opioid substitution treatment (OST), 57, 119
potential new treatments, 119
research needs, 119
intervention delivery platforms in, 12, 29
MNS disorders in, 5
mood and anxiety disorders in, 69
neurological disorders in, 87
suicide surveillance in, 168
survey of mental disorders in, 38
transition from communicable to noncommunicable diseases in, 41
vital registration systems, lack of, 163
lung cancer, 42

M

major depressive disorder. *See* depression
Malaysia, suicide in, 175, 177
MANAS (MANashanti Sudhar Shodh, mental health project in India), 78, 207, 224–25
mania, 69, 71. *See also* bipolar disorder
mass media campaigns. *See* public awareness campaigns
maternal depression. *See* postpartum depression
maternal mental health interventions, 152–53, 212
Mauritius
  preschool program in, 150
  school-based prevention program for adolescent depression in, 222, 229
  school-based social and emotional learning intervention in, 230
Maximizing Independence at Home project, 97
media reporting of suicide and self-harm, 175
medical marijuana, 91
medical vs. moral models of addiction, 12, 119
medications
  access of people with mental disorders to, 48
  for ADHD, 154
  antipsychotics for dementia patients, 53, 96–97
  for conduct disorder, 154
  cost-effectiveness of, 226
  for epilepsy. *See* anti-epileptic drugs (AEDs)
  low-cost generics, 22, 226
  morbidity and mortality rates related to treatment with, 47
  pharmacotherapies
    for dementia, 96–97, 98
    for epilepsy, 90–91
    for headache disorders, 100–101
    for heroin and opioid dependence, 116*t,* 117
    for mood and psychotic disorders, 74, 75–76*t,* 79
    for substance use disorders, 48, 57–58, 118
  prescription monitoring programs, 112–13, 112*t*
  psychotropic medications
    effects of, 48, 56
    primary care staff prescribing, 212
Megiddo, I., 240
memantine, 96, 98
men. *See* gender differences
mental, neurological, and substance use (MNS) disorders, 1, 2. *See also* neurological disorders; *specific types of disorders*
  adults. *See* adult mental disorders
  alcohol abuse. *See* alcohol use disorders
  children. *See* childhood mental and developmental disorders
  disability-adjusted life years (DALYs) due to, 5. *See also* disability-adjusted life years
  economic output lost due to, 8
  mortality rates associated with, 6. *See also* mortality rates
  need for action to address, 22–23
  significance for global health, 5–8
  substance abuse. *See* illicit drug dependence
  years lived with disability (YLDs) and, 5, 6*f*. *See also* years lived with disability
  years of life lost (YLLs) and, 5, 6, 6*f*. *See also* years of life lost
mental disorders. *See* adult mental disorders; childhood mental and developmental disorders; mental, neurological, and substance use (MNS) disorders; *specific disorders (e.g., anxiety, depression)*
mental health awareness campaigns, 73, 186–87. *See also* public awareness campaigns
mental health first aid training, 188, 191, 193, 223
Mental Health Gap Action Programme (mhGAP). *See* World Health Organization (WHO)
mental health legislation, 73. *See also* legislation
mental health workers
  health centers or home visitation programs using, 193
  human resource competencies for MNS disorders in, 210
  low availability of, 12
  pre-service and in-service training of primary care workers, 210
methadone maintenance, 57, 111, 113, 117, 118, 226
Mexico
  alcoholic beverages in
    cost-effectiveness of interventions, 138
    demand reduction strategies for, 229
    unrecorded production of, 133
  illicit substance use in, 111
  school-based social and emotional learning intervention in, 230
mhGAP. *See* World Health Organization
microfinance, 193
Middle East and North Africa
  cost-effectiveness of interventions in, 227*t*
  illicit drug dependence in, 44
  suicide of women in, 171
midwives, role of, 212
migraine. *See also* headache disorders
  burden of disease, 32–34*t,* 87
  cost-effectiveness of interventions for, 228*b*
  DALYs associated with, 36
  deaths associated with, 7*t*
  definition of, 99
  estimated number of cause-specific and excess deaths for, 46*t*
  interventions for, 10*t,* 188
    primary health care, 13–14*t,* 15
    self-care, 15

Mihalopoulos, C., 155, 223
Millennium Development Goals, 214
Mini-Mental State Examination, 96
MNS. *See* mental, neurological, and substance use (MNS) disorders
monitoring and evaluation of interventions, 22
monitoring and reporting systems
  dementia, 213
  suicide and self-harm, 177
mood disorders, 68–70, 75*t*. *See also* anxiety disorders; depression
moral vs. medical model of addiction, 12, 119
morphine maintenance, 117
mortality rates. *See also* Global Burden of Disease Study 2010 (GBD 2010); years of life lost (YLLs)
  for alcohol use disorders, 7*t,* 44, 129
  cause-of-death data, difficulty in capturing, 58–59
  illicit drug dependence, 110–11
  MNS disorders associated with, 6–7, 7*t,* 22, 41
  models used in estimating, 43, 43*f*
  suicide mortality rates, 164, 165*t*
multiple sclerosis, 3, 29, 32–34*t,* 87
multisystem therapy, 155
music therapy, 74
mutual aid groups. *See* support groups

N

naloxone and other emergency responses, 115
naltrexone maintenance, 57, 117, 119
narcotics. *See* illicit drug dependence
National Institute for Health and Care Excellence (NICE), 99
natural history models, 43, 45–46, 48, 49, 59
needle programs, 57
neighborhood factors, 3*b*
neighborhood groups, 192–93, 194. *See also* self-help programs; support groups
neurocysticercosis, 89*b,* 91, 186
neurological disorders, 87–108. *See also* epilepsy; headache disorders
  burden of disease, 30, 32–34*t,* 87
  community health workers' detection abilities, 193
  cost-effectiveness of interventions for, 226
  in elderly persons, 36
  GBD findings of excess mortality for
    estimated number of cause-specific and excess deaths, 46*t,* 51, 51*f*
    implications, 58
  gender differences in, 45, 46*f*
  interventions for, 10*t*
    delivery platforms, 14*t*
    school-based interventions, 189, 192
  YLDs and, 87
  YLLs and
    gender differences and, 45, 46*f*
    regional differences and, 55
New Zealand
  fetal alcohol syndrome (FAS) warning labels in, 135
  indigenous communities, alcohol consumption by, 135
Nigeria
  alcohol use, demand reduction strategies for, 229
  community-based awareness in, 73
  depression in, 69, 70, 208, 225
  epilepsy in, 230
  schizophrenia in, 225, 230
  suicide in, 169
noncommunicable diseases
  compared to communicable diseases in global burden of disease, 30, 36, 41
  integrating mental health into primary care for, 213
nonspecialist human resource cadres, 15, 22
Norwegian dementia mortality study, 52
novel psychoactive substances, 109, 120*n*2

O

obesity, 49, 56–57, 100
obsessive-compulsive disorder (OCD), 70
occupational therapy, 76, 79
Open the Doors program, 187
opioid dependence. *See also* illicit drug dependence
  burden of disease, 32–34*t*
  consumption trends, 111
  DALYs associated with, 36
  deaths associated with, 7*t,* 37, 41
    age of death, 54*t*
  GBD findings of excess mortality for
    estimated number of cause-specific and excess deaths, 46*t,* 50*f,* 51
    implications, 57–58
  illicit opioids, 109
  naltrexone maintenance, 117
  opioid substitution treatment (OST), 57, 113, 114, 118, 119, 120. *See also* methadone maintenance
  prevalence in Australasia and Western Europe, 37
  rates of dependence, 110
  substance use disorders and, 51
  supervised injectable heroin maintenance, 57, 117
  YLLs and, 37, 43
overdose prevention education, 114–15
oxycodone, 111. *See also* opioid dependence

P

Pakistan
  depressive disorder related to suicide in, 169

mental health awareness among school children in, 74
preventive maternal and child health care in, 153
rural secondary schools in, 189
suicide in, 175
depressive disorder related to, 169
women, 171
Thinking Healthy Programme, 212
Palestine, school-based intervention in, 191*b*
panic disorder, 70, 75*t*
parenting interventions, 193
community-based program for, cost-effectiveness of, 222–23
skills training, 152, 213–14
Parkinson's disease
burden of disease, 30, 32–34*t,* 87
gender differences in, 5, 33
peer-led interventions
education, 202
illicit drug dependence, 110
self-help groups and peer support, 203
Perinatal Mental Health Project (South Africa), 212
pesticides
regulation to restrict access to, 17*b,* 176, 185
safe storage of, 176
self-poisoning, 175, 177
Phanthunane, P., T. Vos, 225
pharmacologic treatment. *See* medications
phobias, 70
Pion, S. D. S., 52
Plan Do Study Act, 214
Platania-Phung, C., 56
pneumonia, 53, 56
political will, effect on scaling up, 21
polydrug use, 114, 120*n*5
Pompili, P., 52
population platform interventions, 13–14*t,* 15, 183–87, 193–94
for adult mental health, 73
for alcohol use disorders, 130, 131–35, 131*t*
for childhood mental and developmental disorders, 148–49
for epilepsy, 89
for illicit drug dependence, 112–13, 112*t*
information and awareness campaigns, 186–87
key findings, 183
legislation and regulations, 184–85. *See also* legislation
protecting persons with MNS disorders, 186
restricting access to means of suicide, 185
for suicide, 174–75
postpartum depression, 75*t,* 77, 152–53, 212
women's support groups for, 153
post-traumatic stress disorder (PTSD), 49, 68, 70, 75*t,* 77, 192
poverty. *See also* financial risk protection (FRP)
microfinance schemes and, 193, 221
schizophrenia and, 48
suicide and, 169, 170, 175
Powell, C., 149
precursor chemicals, 112, 112*t,* 120*n*3
pregnancy
alcohol use in, 135, 139
vulnerability for MNS disorders, 185
premature mortality, 5. *See also* years of life lost (YLLs)
Preventing Suicide: A Global Imperative (WHO), 177
prevention of MNS disorders, 4*b,* 8–12, 9–11*t*. *See also* interventions for MNS disorders
adult mental disorders, 76–77
cost-effectiveness of. *See* cost-effectiveness and affordability of interventions
primary health care level, 13–14*t,* 15, 203
for alcohol use disorders, 13–14*t,* 15
competency-based education, 209–10, 209*t*
cost-effectiveness of, 224–27
international studies, 226
national studies, 224–26
evidence-based, 205*t*
for illicit drug dependence, 13–14*t,* 15, 115
planning and consultation, 210
pre-service and in-service training of workers, 210
psychotropic medications, prescription authority for, 212
Prince, M., 44
problem-solving skills therapy (PSST), 155
PRogramme for Improving Mental health carE (PRIME), 209, 231
psychiatric services, 203. *See also* specialist health care delivery
psychosis, 2
extended cost-effectiveness analysis for, 19
interventions for, 8
medications for, 226
primary health care for, 13–14*t,* 15
specialist health care delivery for, 15
psychosocial interventions
for conduct disorder, 154–55
for illicit drug dependence, 117
for malnourished infants, 149
psychosocial life crises and suicide, 169–70
psychotherapy for mood and psychotic disorders, 74, 75–76*t*
psychotropic medications, effects of, 48, 56
PTSD. *See* post-traumatic stress disorder

public awareness campaigns, 186–87, 194
alcohol consumption, 135
headaches, 101, 102
illicit drug dependence, 112*t,* 113
mental health, 73
Public Health Action for the Prevention of Suicide (WHO), 177
public health considerations
alcohol use disorders, 128
health platform related, 208
integrating mental health into existing programs, 212–14
maternal mental health, 153
suicide, 173

Q

quality-adjusted life years (QALYs), 155, 225
quality of care, 15, 214–15. *See also* health care platform interventions

R

RAP-A program, 230, 230*t*
refugees, suicides of, 171–72, 177
rehabilitation
cognitive rehabilitation for dementia, 97
illicit drug dependence, 117
mental disorders, 78
Rehm, J., 133–34, 137, 221
relaxation techniques, 74
religious beliefs and suicide, 172
religious healers, 202
research and development initiatives, 22
for illicit drug dependence, 119, 120
residential facilities, 15–16, 203
for illicit drug dependence interventions, 117
Resourceful Adolescent Programme-Adolescent version (RAP-A) program, 229–30, 230*t*
respiratory diseases, 41, 56
risk factors
for childhood mental and developmental disorders, 146–48, 148*t*
for illicit drug dependence, 110
for suicide, 37, 168–71, 173*f,* 178
risperidone, 226
Russian Federation, headache interventions in, 102, 208, 228*b*

S

Saxena, S., 232
scaling up, 4–5*b*
affordability and. *See* cost-effectiveness and affordability of interventions
case studies of interventions for MNS disorders, 16–17*b*
extended cost-effectiveness analysis for, 19, 21*f*
health system barriers and opportunities for, 21–22
knowledge gaps as factors, 21–22
political will as factor, 21
proposed regional framework in WHO Eastern Mediterranean Region, 23–24*b*
strategies for strengthening health system, 22
schizophrenia, 72–73
age of cause-specific and excess deaths attributed to, 47*f*
burden of disease, 32–34*t*
cannabis dependence and, 53, 55*t*
clinical features and course, 72
co-occurring disorders with, 48
cost-effectiveness of interventions for, 19, 20–21*f,* 225, 227*t,* 230
community-based vs. hospital-based services, 228
extended cost-effectiveness analysis, 242*t*
DALYs associated with, 36
deaths associated with, 7*t*
age of death, 54*t*
environmental factors associated with, 68
epidemiology and burden of disease, 72–73
estimated number of cause-specific and excess deaths for, 46–48, 46*t,* 47*f*
extended cost-effectiveness analysis for, 19, 21*f,* 241–45
gender differences in, 5, 33, 68
genotyping of individuals with, 68
interventions for. *See also* adult mental disorders
enhanced financial and service coverage, 241–43
pharmacologic and psychological treatment, 76*t*
side effects of antipsychotic medications for, 48
suicide and self-harm and, 48
YLDs and, 68, 68*f*
YLLs and, 43, 45*f,* 48
schools. *See* education and schools
Scott, D., 56
screenings
for alcohol use disorders, 135–36, 136*t,* 139
for childhood mental and developmental disorders, 151–52, 156
for comorbid health issues, 56–57
for dementia, 98
for illicit drug dependence, 115, 117
for mental health disorders, 77
SDG (sustainable development goal), 2*b*
self-care, 13–14*t,* 15, 202–3
for epilepsy, 90
evidence-based, 205*t*
for headache disorders, 100
for mood and psychotic disorders, 74

self-harm. *See* suicide and self-harm
self-help programs, 57, 202–3
  for alcohol use disorders, 136–37
  for illicit drug dependence, 114, 115*t*
self-immolation. *See* suicide and self-harm
serotonin-norepinephrine reuptake inhibitors (SNRIs), 225
Service Organization Pyramid for an Optimal Mix of Services for Mental Health (WHO), 202, 202*f*
sexual minorities, suicide of, 172
shame and fear, 67
SHR (sustained headache relief), 100
simple phobias, 70
Single Convention on Narcotic Drugs, 120*n*1
Six Sigma, 214
Skeen, S., 194
smoking, 47–48, 49, 52, 56–57
Sneha (suicide prevention organization), 175
sobriety checkpoints, 134
social anxiety disorder, 70
social causation pathway, 3*b*
social change, 3*b*
social determinants, 1, 3*b*
  for illicit drug dependence, 110
social drift pathway, 3*b*
societal response to alcohol use disorders, 130
socioeconomic status, 3*b*. *See also* poverty
  drinking and, 129
  schizophrenia and, 48
SOLVE training package, 188
Sornpaisarn, B., 133
South Africa
  alcohol consumption of pregnant women in, 135
  collaborative stepped care approach in, 210
  epilepsy treatment in, 89
  HealthWise program in, 190, 190*b*
  HIV/AIDS treatment integrated with mental health in, 214
  parenting skills training in, 152
  Perinatal Mental Health Project, 212
  Primary Care 101 (PC101), 214
  primary care practitioners in, 208
  workplace interventions in, 189
South Asia
  alcohol consumption in
    cost-effectiveness of interventions, 137, 221
    taxation, 133, 137
  cost-effectiveness of interventions in, 226, 227*t,* 231, 239
  suicide prevention organizations in, 176
  suicide rates in, 164
  traditional medicine in, 202
specialist health care delivery, 15, 74–76, 203
  for alcohol use disorders, 15
  for childhood mental and developmental disorders, 154–55
  cost-effectiveness of, 228–29
  evidence-based, 205*t*
  for extended-stay facilities, 203
  for illicit drug dependence, 15, 116–17, 116*t*
Sri Lanka
  children with developmental delays in, 151
  suicide in, 170, 171, 175, 177–78
    prevention through pesticide regulation, 17*b,* 185, 185*b*
    safe storage of pesticides, 176
START (STrAtegies for RelaTives) study, 99
Statistical Process Control, 214
stigma and discrimination, 1, 5*b,* 22, 67
  anti-stigma interventions, 89–90, 187
  limiting access to interventions, 12
  limiting access to screenings, 56
  quality of care and, 214
  self-care and, 203
  suicide and, 175, 176
Strang, J., 8
stroke, 41, 56
Sub-Saharan Africa
  alcohol consumption in, 129
    cost-effectiveness of interventions, 137, 221
    mortality associated with, 129
    taxation, 133, 137
  childhood mental disabilities, lack of data on, 146
  cost-effectiveness of interventions in, 221, 226, 227*t,* 231, 239
  epilepsy in, 44, 45, 52, 89, 91
  human resource competencies for MNS disorders in, 210
  illicit drug dependence in, 44
    cost-effectiveness of interventions, 118
  microfinance in, 193
  traditional medicine in, 202
  YLL rates in, 44, 45–46*f,* 55
    gender differences and, 45, 46*f*
substance use disorders. *See* illicit drug dependence
suicide and self-harm, 42, 163–81
  of adolescents, 171
  age pattern of, 164, 165*t,* 166–67*f*
  alcohol consumption and, 50, 129, 169, 175
  as cause of death, 41, 164
  changes in rates (2000-12), 164, 165*t*
  coping strategies and well-being, 172
  cost-effectiveness of prevention efforts, 178
  decriminalization of, 175
  definition of, 163

depression and, 69, 176
drug misuse and, 175
early traumatic events associated with, 170–71
economic issues and, 175
effective interventions for, 11*t*
epidemiology, 163
epilepsy and, 52
exposure to models, 170
family history of suicide, 170
of farmers, 171
gender differences, 164, 165*t,* 166–67*f,* 171
interventions for, 11*t,* 174–78
brief intervention and contact, 177
community platform interventions, 175–76
delivery platforms, 14*t*
disasters and refugees, 177
examination stress, 175
gatekeeper training, 176
health care platform interventions, 177–78
medical management of poisoning with pesticides, 177
monitoring and reporting systems, 177
national suicide prevention strategies, 177–78
nongovernmental organization services, 175–76
population platform interventions, 174–75, 194
restricting access to lethal means, 17*b,* 174–75, 176, 185, 194, 222
safe storage of pesticides, 176
school-based interventions, 176
stigma and discrimination, 175
media reporting of, 175
mental disorders and alcohol misuse associated with, 169
methods, availability of, 168, 170
pesticide self-poisoning, 175, 177
Sri Lanka suicide prevention through pesticide regulation, 17*b,* 185*b*
physical disorders and, 169
prevention in LMICs, 172–74
prior suicide attempts, 170
protective factors, 172
psychosocial life crises and, 169–70
as public health issue, 173
of refugees and internally displaced persons, 171–72, 177
religious and spiritual beliefs, 172
risk factors for, 37, 168–71, 173*f,* 178
schizophrenia and, 48
of sexual minorities, 172
stigma of, 176
strong personal relationships and, 172
substance use disorders and, 51, 55*t,* 110
suicide attempt rates, 164–68
suicide mortality rates, 164, 165*t*
surveillance in LMICs, 168
survivors of suicide loss, 172
urban vs. rural locations, 170
WHO prevention guidelines, 57, 163, 173
YLLs and, 53, 55
supervised injecting facilities, 57, 115
support groups, 192–93, 194. *See also* self-help programs
for alcohol use disorders, 136–37
for illicit drug dependence, 114, 115*t*
suspension of driver's license, 135
sustainable development goal (SDG), 2*b*
sustained headache relief (SHR), 100
Sweden
cost of Alzheimer's disease treatment in, 98
dementia-related deaths in, 53
epilepsy-related deaths in, 52
Szekely, A., 176

T

Tanzania
epilepsy-related deaths in, 52
epilepsy treatment in, 89
task-sharing approach, 209–12, 210*b*
taxation of alcoholic beverages, 131*t,* 132–33, 138, 221, 229
Taylor, B. J., 133–34
teacher training program to identify and assess mental health problems, 191, 191*b*
TEAMcare USA and TEAMcare Canada, 213
telemedicine, 78
Ten Questions screen, 151, 151*b*
testing
blood alcohol concentration (BAC) testing of drivers, 134
breath testing of drivers, 134
Thailand
alcoholic beverages, regulation of, 128
antidepressants and CBT as cost-effective interventions for depression in, 225
therapeutic community (TC) model, 117
Thinking Healthy Programme (Pakistan), 212
3 Dimensions of Care for Diabetes (UK), 213
Total Quality Management, 214
TPO (Healthnet Transcultural Psychosocial Organization), 17*b*
traditional healers, 202
traffic accidents. *See* driving impaired and traffic accidents
transcranial magnetic stimulation, 74
traumatic brain injury, measures to protect against, 186

treatment gap, 214
in epilepsy, 58, 92*f*
treatment of MNS disorders, 4*b,* 8–12, 9–11*t*. *See also* interventions for MNS disorders
cost-effectiveness of. *See* cost-effectiveness and affordability of interventions
Ttofi, M. M., 150
tuberculosis, 50, 129, 212, 213–14
Turkey
early childhood enrichment project in, 192
suicide in, 170, 171

U

Uganda
epilepsy treatment in, 89
specialists training primary health care staff in, 210
United Kingdom
Alzheimer's disease, pharmacological interventions for, 98
bipolar disorder research in, 48
cognitive rehabilitation for dementia in, 97
community-based awareness in, 73
community-based vs. hospital-based programs in, 73
coping strategy program for mental health of dementia caregivers in, 225
crisis intervention teams in, 77
epilepsy-related deaths in, 52
parenting programs in, 223
3 Dimensions of Care for Diabetes, 213
United Nations
Children's Fund Multiple Indicator Cluster Survey, 151
Convention on the Rights of Persons with Disabilities, 215
United States
court-mandated drug treatment in, 113
depression in, 69
Drug Abuse Resistance Education (DARE) program, 114
fetal alcohol syndrome (FAS) warning labels in, 135
Good Behavior Game for classroom behavior management with young children, 114
stroke awareness program for children in, 189
TEAMcare USA, 213
universal health coverage, 5*b,* 18*b,* 19, 237–51. *See also* extended cost-effectiveness analysis (ECEA)
health system goals, 237
MNS coverage, 237–38
pay out-of-pocket (OOP) for treatment, 237–38
University of Washington's Institute for Health Metrics and Evaluation, 38
unrecorded market of alcohol production and sales, 133, 138–39
urinary tract infections, 53

V

vicious cycle of social determinants, 3*b*
violence
alcohol-attributable, 50, 129
domestic violence legislation, 186
Vreeman, R. C., 150

W

warning labels on alcoholic beverages, 135, 139
web-based psychological therapy, 15, 78
Whiteford, H. A., 31
WHO. *See* World Health Organization
whole-of-government approach, 205
whole-of-school approach, 150
women. *See also* gender differences; pregnancy
gender equity and economic empowerment interventions, 193
postnatal depression. *See* postpartum depression
suicide rates of, 171
workplace interventions, 194
drug testing, 113–14, 115*t*
epilepsy, anti-stigma interventions for, 89
identification and case detection, 188
mood and anxiety disorders intervention, 73
promotion and primary prevention, 188
World Development Report (1993), 2*b*
World Health Organization (WHO)
Assessment Instrument for Mental Health Systems (WHO-AIMS) survey, 73
Atlas on Substance Use, 137
Building Back Better, 204
Child and Adolescent Mental Health Policies and Plans, 148
CHOosing Interventions that are Cost-Effective (CHOICE) project, 220, 226, 228, 228*b,* 232
Comprehensive Mental Health Action Plan, 22, 24
cost-effectiveness analysis, 18
detection of mental disorders, system for, 77
Global Health Estimates, 5, 163, 166*f*
High-Level Meeting on Non-communicable Diseases (2011), 229
Integrated Management of Adult and Adolescent Illness (IMAI), 213
List of Essential Medicines, 57
Mental Health Gap Action Programme (mhGAP), 1, 5, 8, 17*b,* 22, 74, 77, 204, 245
alcohol consumption and, 135, 136
depression and, 208
Mental Health Global Action Program, 177

Ministerial Conference on Global Action Against Dementia (2015), 99
noncommunicable disease interventions package, 213
Preventing Suicide: A Global Imperative, 177
proposed regional framework in Eastern Mediterranean Region, 23–24*b*
Public Health Action for the Prevention of Suicide, 177
on quality improvement (QI) mechanisms, 214
QualityRights Project, 186
QualityRights Toolkit, 215
recommended method for integrating hospital-based and community-based mental health services, 16*b*
Service Organization Pyramid for an Optimal Mix of Services for Mental Health, 202, 202*f*
on suicide and suicide prevention, 57, 163, 173, 177, 178
World Mental Health Action Plan (2013-2020), 177
World Mental Health (WMH) surveys, 69–70, 71, 102, 166
YLDs assigned to MNS disorders, 30
World Psychiatric Association, 187

Y

years lived with disability (YLDs), 5, 6*f,* 30–31, 35, 35*f,* 37
adult mental disorders, 67–68, 68*f*
epilepsy, 90
from natural history models, 43
neurological disorders, 87
population attributable fractions (PAFs) and, 44
schizophrenia, 68, 68*f*
years of life lost (YLLs), 5, 6, 6*f,* 30–31, 35, 35*f,* 37, 41
alcohol use disorders, 43–45, 45*f,* 53, 55, 55*t*
amphetamine dependence, 43
attributions needed for more accurate representation of MNS disorders, 55
cause of death and, 42–43, 46, 53–55
cocaine dependence, 43
dementia, 43, 45*f*
depression, 49
differences in patterns of MNS prevalence and, 44–45, 45*f*
gender differences, 45, 46*f*
illicit drug dependence, 45*f,* 53, 110
gender differences and, 45, 46*f*
natural history models and, 45–46
neurological disorders
gender differences and, 45, 46*f*
regional differences and, 55
opioid dependence, 37, 43
population attributable fractions (PAFs) and, 44
regional differences and, 53–54, 55*f*
schizophrenia, 43, 45*f,* 48
suicide and, 53, 55

Z

Zambia
epilepsy treatment in, 90
headache disorders and treatment in, 100, 102, 228*b*
trauma-focused CBT for children in, 154